SRRK Scholar Rock Holding Corp

BMO Capital reiterated $SRRK Outperform-$76 and said -- Physician Expert Survey Supports Broad Uptake of Apitegromab in SMA $RHHBY $NVS BIIB - IONS PTCT LLY NVO BMY REGN BMO Capital added—Proprietary physician survey points to broad potential usage of Scholar Rock's apitegromab on top of SMN-directed therapy for patients with spinal muscular atrophy (SMA). Key takeaways from neurologist survey (n = 15) 1) Broad potential eligibility, with 62% of SMN-treated patients viewed as candidates; 2) strong physician interest, with 73% of surveyed physicians planning to prescribe within six months; and 3) adoption driven primarily by motor-function improvement and clean safety. These results support our bullish view of Scholar Rock shares into the September 30, 2026, PDUFA.

$SRRK Day 2 of a mega sell a thon after getting FDA approval 2 weeks early- never dremt this would have gone this way.

Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours $SRRK $VTI $IWM https://stocktwits.com/news/equity/markets/second-time-s-the-charm-fda-clears-scholar-rock-s-sma-drug-ahead-of-deadline-srrk-soars-15-after-hours/cZtXymnRBbS

$SRRK Feels like a freefall now....no strength...completely befuddled. Stock was trading 30% higher in AF after winning first approval...the down move is stunning

$SRRK We need to rally and close at or above 49.5 to kick the junior math player out of the lead. Right now they are justifying their bonus from the market makers too easily.

$SRRK insane to see full derisking of the stock and FDA approval… to a complete sell-off. Fully expect a rebound once retail takes profits but still…

$SRRK this looks a little oversold here above the Lower Bollinger band may be a good opportunity here for a little bit of a bounce anyway

$SRRK Bulls are getting wrecked here on FDA approval news, Wow! This market is laughable.

$SRRK Buy BMO raises target price to $84 from $76 Canaccord Genuity raises PT to $72 from $62 Citigroup raises target price to $74 from $60 Truist Securities raises PT to $76 from $55

$SRRK I am completely lost on this one...so company wins its first approval - ever - and I am well aware of the manufacturing challenges/baked in price/etc - but I cannot recall a selloff like this in the face of milestone achievement for the company. What am I missing?

$SRRK Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) https://www.businesswire.com/news/home/20260911564629/en/Scholar-Rock-Announces-FDA-Approval-of-ISEMBYLD-apitegromab-mstn-the-First-and-Only-Muscle-Targeted-Treatment-for-Children-and-Adults-with-Spinal-Muscular-Atrophy-SMA

$SRRK we lost like -6M shares the last 4 days-one of these guys closed out-most likely Redmile.

$SRRK seems that FDA is requiring post marketing bone and pregnancy safety data. This was supposed to be announced on approval release but FDA gave an update today. 

$SRRK The firm ended June with $492 million in cash, can draw another $150 million of debt, and plans to sell a priority-review voucher. It said it does not intend to raise equity now.

SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets $SRRK $VTI $IWM https://stocktwits.com/news/equity/markets/srrk-shares-pull-back-after-fda-approval-for-genetic-disease-drug-but-wall-street-hikes-price-targets/cZtmh4bRBT3

$SRRK should get a nice pop after fda approval. This is a game changer in its respective field. When they start cash flow should be 100+

SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing $SRRK $VTI $IWM $NVO https://stocktwits.com/news/equity/markets/srrk-stock-gains-after-company-drops-troubled-novo-nordisk-owned-plant-from-fda-filing/cZY97AgRJVf